John Robinson, DO
Gynecologic Oncology · Wilmington, NCNPI 1699900191
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $700 of the $1,041 with a category attached, or 67.3%. 12 manufacturers reported payments, led by Intuitive Surgical at 32.7% of the total. Reporting peaked in 2019 at $573 and has fallen 93.9% since, to $35 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in NC, where the typical reported total is $1,376.
Across 23 payments — averaging $45.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$341
- Merck$335
- AstraZeneca$183
- Foundation Medicine, Inc.$38
- Daiichi Sankyo Inc.$27
- Mimedx Group, Inc.$20
- plus $96 from 6 others
What the payments were for
- Travel & lodging$34133%
- Food & beverage$70067%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 1 | $341 |
| Merck | 8 | $335 |
| AstraZeneca(2 entities) | 4 | $183 |
| Foundation Medicine, Inc. | 2 | $38 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Mimedx Group, Inc. | 1 | $20 |
| Sobi, Inc | 1 | $17 |
| Masimo Corporation | 1 | $17 |
| Genmab U.S., Inc. | 1 | $17 |
| Tersera Therapeutics LLC | 1 | $17 |
| Medtronic | 1 | $14 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$341
- LYNPARZA$125
- KEYTRUDA$124
How this compares
$1,041 in reported general payments places this provider in the 40th percentile of 52 gynecologic oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 12 | $11,478 |
| EliquisApixaban | 11 | $6,418 |
| Dexamethasone | 30 | $440 |
| Ondansetron Hcl | 49 | $280 |
| Prochlorperazine Maleate | 28 | $229 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 14 | $166 |
| Oxycodone Hcl | 18 | $108 |
| Gabapentin | 13 | $108 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Wilmington
- Lucybeth Nieves ArribaWilmington$251K
- Lindsey BuckinghamWilmington$2K
- Walter GajewskiWilmington$496
- Robert NaumannCharlotte$221K
- Angeles SecordDurham$121K
- Erin CraneCharlotte$98K
- Michael SundborgSouthern Pines$85K
- William LoweryDurham$67K
- Emma RossiGreensboro$62K
- Jubilee BrownCharlotte$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.